John Fitzgerald

Dr. John Fitzgerald


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in JACC: Heart Failure
Verified
Journal Article
Closed access
JAJonathan P. Ariyaratnam
Jonathan P. Ariyaratnam
RMRicardo S. Mishima
Ricardo S. Mishima
KKKadhim Kadhim
Kadhim Kadhim
MEMehrdad Emami
Mehrdad Emami
JFJohn Fitzgerald
John Fitzgerald
AEAdrian D. Elliott
Adrian D. Elliott

19 July 2016 in Drug Safety
Verified
Journal Article
Closed access
PDF file
JFJohn Fitzgerald
John Fitzgerald
Laurence Guy HowesLaurence Guy Howes
Laurence Guy Howes

1 October 2021 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
JNJoan Jacques Noubiap
Joan Jacques Noubiap
JFJohn Fitzgerald
John Fitzgerald
CGCeline Gallagher
Celine Gallagher
GTGijo Thomas
Gijo Thomas
MMMelissa E. Middeldorp
Melissa E. Middeldorp
PSPrashanthan Sanders
Prashanthan Sanders

1 June 2021 in IJC Heart & Vasculature
Verified
Journal Article
Open access
JNJoan Jacques Noubiap
Joan Jacques Noubiap
TAThomas Agbaedeng
Thomas Agbaedeng
JKJoseph Kamtchum-Tatuene
Joseph Kamtchum-Tatuene
JFJohn Fitzgerald
John Fitzgerald
MMMelissa E. Middeldorp
Melissa E. Middeldorp
PSPrashanthan Sanders
Prashanthan Sanders
To summarize data on atrial fibrillation (AF) detection rates and predictors across different rhythm monitoring strategies in patients with cryptogenic stroke (CS) or embolic stroke of undetermined source (ESUS). MEDLINE, Embase, and Web of Science were searched to identify all published studies providing relevant data through July 6, 2020. Random-effects meta-analysis method was used to pool estimates. We included 47 studies reporting on a pooled population of 8,215 patients with CS or ESUS. Using implantable cardiac monitor (ICM), the pooled rate of AF was 12.2% (95% CI 9.4–15.0) at 3 months, 16.0% (95% CI 13.2–18.8) at 6 months, 18.7% (95% CI 15.7–21.7) at 12 months, 22.8% (95% CI 19.1–26.5) at 24 months, and 28.5% (95% CI 17.6–39.3) at 36 months. AF rates were significantly higher in patients with ESUS vs CS (22.0% vs 14.2%; p < 0.001) at 6 months, and in studies using Reveal LINQ vs Reveal XT ICM (19.1% vs 13.0%; p = 0.001) at 12 months. Using mobile cardiac outpatient telemetry (MCOT), the pooled rate of AF was 13.7% (95% CI 10.2–17.2) at 1 month. Predictors of AF detection with ICM included older age, CHA2DS2-VASc score, left atrial enlargement, P wave maximal duration and prolonged PR interval. The yield of ICM increases with the duration of monitoring. More than a quarter of patients with CS or ESUS will be diagnosed with AF during follow-up. About one in seven patients had AF detected within a month of MCOT, suggesting that a non-invasive rhythm monitoring strategy should be considered before invasive monitoring.

1 January 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JNJoan Jacques Noubiap
Joan Jacques Noubiap
TAThomas Agbaedeng
Thomas Agbaedeng
JTJoel Noutakdie Tochie
Joel Noutakdie Tochie
JNJan René Nkeck
Jan René Nkeck
ANAude Laetitia Ndoadoumgue
Aude Laetitia Ndoadoumgue
PSPrashanthan Sanders
Prashanthan Sanders

Verified
Journal Article
Open access
PDF file
JFJohn Fitzgerald
John Fitzgerald
MMMelissa E. Middeldorp
Melissa E. Middeldorp
CGCeline Gallagher
Celine Gallagher
PSPrashanthan Sanders
Prashanthan Sanders
Management of atrial fibrillation (AF) requires a comprehensive approach due to the limited success of medical or procedural approaches in isolation. Multiple modifiable risk factors contribute to the development and progression of the underlying substrate, with a heightened risk of progression evident with inadequate risk factor management. With increased mortality, stroke, heart failure and healthcare utilisation linked to AF, international guidelines now strongly support risk factor modification as a critical pillar of AF care due to evidence demonstrating the efficacy of this approach. Effective lifestyle management is key to arrest and reverse the progression of AF, in addition to increasing the likelihood of freedom from arrhythmia following catheter ablation.